Saffron Walden, UK, 21st January 2021 / Domainex Ltd., a leading provider of integrated drug discovery services, is pleased to welcome David Cronk, CBiol, MRSB, to the team as its new Chief of Staff. The Company has also promoted long standing team member and previous Head of Chemistry, Dr Ray Boffey, to Executive Director of Medicines Research. Following a successful period of growth and expansion of its research team, both David and Ray bring a wealth of drug discovery experience and will further support Domainex’s ongoing growth plans.
David Cronk has over 30 years’ drug discovery…
The cfPure® Cell Free DNA Extraction Kit from AMSBIO is a magnetic bead-based DNA extraction kit designed to isolate circulating cell free DNA (cfDNA) from human plasma or serum samples.Using a quick, simple, and automation friendly protocol the kit allows users to quickly extract high quality cfDNA that is ready for use in downstream applications including next-generation sequencing, Bisulfite Sequencing, PCR, qPCR, ddPCR and other demanding applications. This optimized protocol gives highly reproducible results and higher yields relative to other magnetic bead-based methods.…
Research Triangle Park, NC, USA and Cambridge, UK, 20 January 2021 – Inivata, a leader in liquid biopsy, today announces that the first patients have been tested using InVisionFirst®-Lung as part of the Phase II ALKALINE trial sponsored by the European Organisation for Research and Treatment of Cancer (EORTC). As part of the study Inivata’s InVisionFirst-Lung liquid biopsy will be used to test and monitor ALK positive non-small cell lung cancer (NSCLC) patients initiating treatment with lorlatinib, Pfizer Inc.’s third generation ALK inhibitor therapy.
The aim of this academic trial, announced…
Cambridge and London, UK, 18 January 2021:
Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement.
The collaboration is focused on the discovery of novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis, and has now…
Cambridge, United Kingdom – 14 January 2021 - Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with the Congenica Board of Directors and wider senior leadership team, this group of leading advocacy professionals and experts in rare diseases, genetics and precision medicine will ensure that the patient perspective remains at the heart of Congenica’s strategy. Alongside this, the new board will serve to inform patients and…
Taiho Pharmaceutical Co, Ltd., (hereinafter Taiho) announces that it and Astex Pharmaceuticals (UK), (hereinafter Astex), both Otsuka group companies, have granted an exclusive license under their joint, small-molecule drug discovery program targeting SHP2 to Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada (hereinafter MSD) through a subsidiary.
An option for MSD to acquire the exclusive license to the Astex-Taiho SHP2 program was included as part of the strategic oncology collaboration between MSD, Astex and Taiho, announced in January 2020…
Cambridge, UK, 13 January 2021: Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, was honored with a Employees’ Choice Award recognizing the Best Places to Work in 2021 by Glassdoor, the worldwide leader on insights about jobs and companies.
Nick Skinner, SVP Human Resources at Abcam commented: “I am delighted by the positive feedback received from our employees, especially over the past year. Delivering our ambitious strategy depends on our engaged global team and I am proud of what we’ve achieved together. We continuously strive to better support the…
Cambridge animal health technology pioneer PetMedix has clinched a multi-year partnership with Boehringer Ingelheim to develop novel and transformative companion animal antibody therapeutics using PetMedix's proprietary Ky9™ platform.
As part of the collaboration, PetMedix will undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market.
The companies refuse to disclose financial details of the tie-up.
While there are many technologies that have been used to develop human therapeutic antibodies,…
Cambridge, UK, 12 January 2021: CN Bio, a leading developer of single and multi organ-on-chip microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, today announced the publication of co-authored research with the U.S. Food and Drug Administration (FDA)1. The first co-published, peer-reviewed research paper between a commercial MPS provider and a regulator, demonstrates that data derived using CN Bio’s proprietary PhysioMimix™ system is appropriate for use in drug safety and metabolism applications, evidencing its enhanced performance versus standard…
Tokyo, Japan and Cambridge, UK, 12 January 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases.
The collaboration will combine Sosei Heptares’ world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability…